Key result
Aspirin for primary prevention in 65-year-old women with moderate cardiovascular risk cost $13,300 per additional QALY gained compared to no therapy.
Why the study?
Is aspirin cost-effective for the primary prevention of cardiovascular disease in women?
Is aspirin cost-effective for the primary prevention of cardiovascular disease in women?
Aspirin use for primary prevention in older women with moderate cardiovascular risk appears to have a favorable cost-utility ratio, though evidence is limited.
No takes yet. Share an insight, caveat, or question.
May support aspirin primary prevention in moderate-risk older women at low cost per QALY; leaves open confirmation amid evolving risks and therapies.
Michael Pignone (2007) studied Primary prevention of cardiovascular disease. Aspirin vs. No therapy was evaluated on Cost per quality-adjusted life-year (QALY) gained. Aspirin for primary prevention in 65-year-old women with moderate cardiovascular risk cost $13,300 per additional QALY gained compared to no therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: